Clinical Trials Arena May 16, 2025
Experts predict growing pains as the life sciences sector moves to adapt to the EU AI Act.
The EU Artificial Intelligence (AI) Act may protect citizens, but some experts in the life sciences industry are worried about the potential challenges it may raise for business.
As AI continues to permeate the drug development pathway, major players like Eli Lilly, Sanofi, and BioNTech have incorporated the technology into their development pathways through major deals. Meanwhile, NVIDIA has also forged several partnerships, including some with smaller companies like Gain Therapeutics, to propel their AI platforms, as well as therapies, to major market success over the next few years. Gain’s work with the technology giant under the NVIDIA Connect program aims to...
Today's Sponsors
Today's Sponsor